Parenteral solutions containing metolazone
Disclosed herein are parenteral solutions containing 7-halo-1,2,3,4-tetrahydro-3-aryl-6-quinazoline sulfonamide in N,N-dimethylacetamide, polyethylene glycol and D 5 W useful in the treatment of hypertension, heart failure and renal disease leading to edematous states. Also disclosed are methods for preparing such solutions.
1. A method of a treating a patient suffering from an edema, comprising: parenterally administering to the patient suffering from an edema a therapeutically effective amount of a solution, comprising: 1 to 15 mg/mL metolazone dissolved in up to 2% by volume N,N-dimethylacetamide (DMAC) and the remainder being 5% dextrose solution (D 5 W), wherein the pH of the solution is from 6.8-8.
2. The method of claim 1 , wherein the pH of the solution is from 7.5-8.
3. The method of claim 1 , wherein the metolazone is dissolved in 1% by volume DMAC, and the remainder being D 5 W.
4. The method of claim 1 , wherein the metolazone is dissolved in 2% by volume DMAC, and the remainder being D 5 W.
5. The method of claim 1 , wherein 5 mg/mL of metolazone is present.
6. The method of claim 1 , wherein 15 mg/mL of metolazone is present.
7. The method of claim 1 , wherein 5 mg/mL of metolazone is present and dissolved in 1% by volume DMAC and the remainder being D 5 W.
8. The method of claim 7 , wherein the pH is 7.5-8.
9. The method of claim 1 , wherein 15 mg/mL of metolazone is present and dissolved in 1% by volume DMAC and the remainder being D 5 W.
10. The method of claim 9 , wherein the pH is 7.5-8.
11. The method of claim 1 , wherein 5 mg/mL of metolazone is present and dissolved in 2% by volume DMAC and the remainder being D 5 W.
12. The method of claim 11 , wherein the pH is 6.8.
13. The method of claim 1 , wherein the edema is caused by congestive heart failure, renal failure, or hepatic failure.
14. The method of claim 1 , wherein the edema is caused by congestive heart failure.
15. The method of claim 1 , wherein the edema is caused by renal failure.
16. The method of claim 1 , wherein the edema is caused by hepatic failure.
17. The method of claim 1 , further comprising: administration of therapeutically effective amount of furosemide.
18. The method of claim 17 , wherein the furosemide is administered parenterally.